AC138517.1 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
ATP10B | ATPase, class V, type 10B | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
B3GALT1 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT3 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT6 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 (core 3 synthase) | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
C15orf48 | Chromosome 15 open reading frame 48 | | | | | | Tissue enhanced |
C9orf152 | Chromosome 9 open reading frame 152 | | | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA7 | Carbonic anhydrase VII | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
CCL15 | Chemokine (C-C motif) ligand 15 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD70 | CD70 molecule | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CEA | Uncharacterized protein | Predicted secreted proteins
| | | | | Tissue enhanced |
CEACAM1 | Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CLDN23 | Claudin 23 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CLDN3 | Claudin 3 | Cancer-related genes Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CPA6 | Carboxypeptidase A6 | Disease related genes Enzymes Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DHRS9 | Dehydrogenase/reductase (SDR family) member 9 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EFNA2 | Ephrin-A2 | Cancer-related genes Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ENTPD8 | Ectonucleoside triphosphate diphosphohydrolase 8 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FAM3D | Family with sequence similarity 3, member D | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FAM84A | Family with sequence similarity 84, member A | | | | | | Tissue enhanced |
FOXD2 | Forkhead box D2 | Transcription factors
| | | | | Tissue enhanced |
FRMD1 | FERM domain containing 1 | Cytoskeleton related proteins
| | | | | Tissue enhanced |
FUT3 | Fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group) | Blood group antigen proteins Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
FXYD3 | FXYD domain containing ion transport regulator 3 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GALNT5 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5) | Enzymes
| | | | | Tissue enhanced |
GCNT3 | Glucosaminyl (N-acetyl) transferase 3, mucin type | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
HAVCR1 | Hepatitis A virus cellular receptor 1 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
HEPACAM2 | HEPACAM family member 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
HOXB9 | Homeobox B9 | Transcription factors
| | | | | Tissue enhanced |
HOXD12 | Homeobox D12 | Transcription factors
| | | | | Tissue enhanced |
HPDL | 4-hydroxyphenylpyruvate dioxygenase-like | | | | | | Tissue enhanced |
KLK15 | Kallikrein-related peptidase 15 | Cancer-related genes Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
LGALS4 | Lectin, galactoside-binding, soluble, 4 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
LIPH | Lipase, member H | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
LRRC19 | Leucine rich repeat containing 19 | Predicted membrane proteins
| | | | | Tissue enhanced |
LRRC31 | Leucine rich repeat containing 31 | | | | | | Tissue enhanced |
LY75-CD302 | LY75-CD302 readthrough | Predicted membrane proteins
| | | | | Tissue enhanced |
MISP | Mitotic spindle positioning | Cytoskeleton related proteins
| | | | | Tissue enhanced |
MUC4 | Mucin 4, cell surface associated | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
NEU4 | Sialidase 4 | Enzymes
| | | | | Tissue enhanced |
NOXO1 | NADPH oxidase organizer 1 | FDA approved drug targets
| | | | | Tissue enhanced |
NPY4R | Neuropeptide Y receptor Y4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
NRARP | NOTCH-regulated ankyrin repeat protein | | | | | | Tissue enhanced |
NTSR1 | Neurotensin receptor 1 (high affinity) | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
NXPE2 | Neurexophilin and PC-esterase domain family, member 2 | Predicted membrane proteins
| | | | | Tissue enhanced |